Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03387579
Other study ID # 1708745276
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date November 30, 2018
Est. completion date March 19, 2024

Study information

Verified date June 2024
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Intestinal failure associated liver disease is a cholestatic liver disease associated with prolonged need for parenteral nutrition that can lead to such significant complications as liver failure. In the neonatal population, infants with history of intestinal resection and short bowel syndrome are at increased risk for this disease. The investigators plan to compare two possible lipid dosing preventative strategies including a composite, fish oil lipid and soy-based lipid reduction.


Description:

Intestinal failure associated liver disease (IFALD) is a cholestatic liver disease associated with prolonged need for parenteral nutrition. This disease can lead to such serious complications as liver failure and need for transplantation. In the neonatal population, short bowel syndrome, due to intestinal resection, is the most common cause of intestinal failure. While the exact cause is yet to be determined, it is felt the lipid component of parenteral nutrition is a large contributor to the development of this disease. Currently, there is no standard preventative strategy to attempt to decrease the risk of IFALD in the high risk, post-surgical neonatal population. The investigators aim to complete a randomized trial comparing two possible preventative strategies. One group will receive a composite lipid containing fish oil (Smoflipid) and the other group will receive soy-based lipid at reduced dosing.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date March 19, 2024
Est. primary completion date March 28, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: Neonates with anticipated need for parenteral nutrition (based on primary physicians opinion) for greater than or equal to four weeks and one of the following diagnoses: - Anatomic: Neonate with intestinal atresia, omphalocele, gastroschisis, or volvulus with or without intestinal resection. - Ischemic/perforation: Neonates with spontaneous intestinal perforation or necrotizing enterocolitis requiring surgical intervention. Exclusion Criteria: - Current weight less than 750 grams - AST or ALT greater than 5 times the upper limit of normal within 2 weeks of enrollment - Direct bilirubin greater than 2 mg/dL on any consecutive measurements 5 - 7 days apart within 2 weeks of enrollment - Severe coagulopathy with INR greater than 95th percentile for age (>1.7 at less than 5 days of age, > 1.5 older than five days of age) - Culture confirmed sepsis with positive blood, urine, or CSF culture within 2 weeks of enrollment - Renal failure requiring dialysis - Cyanotic heart disease requiring prostaglandin therapy - Hypertriglyceridemia (greater than 250mg/dL) at time of enrollment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Smoflipid 20% Lipid Emulsion for Injection
Intravenous lipid containing soy, MCT, olive, and fish oils at goal doses of 3 g/kg/day
Intralipid, 20% Intravenous Emulsion
Intravenous lipid emulsion of 20% soy oil at goal doses of 1 g/kg/day
Intralipid, 20% Intravenous Emulsion
Intravenous lipid emulsion of 20% soy oil at goal doses of 2-3 g/kg/day

Locations

Country Name City State
United States Riley Hospital for Children at IU Health Indianapolis Indiana

Sponsors (1)

Lead Sponsor Collaborator
Indiana University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Cholestasis Cholestasis was defined as a direct bilirubin > 2 mg/dL on two measurements 5 to 7 days apart. Patients were monitored during time enrolled in study for a maximum of up to 12 weeks or 84 days.
Secondary Weight Velocity Weight velocity was calculated as the difference in weight from end to start of study divided by number of days enrolled in study. Patient weight was recorded at enrollment, weekly during time enrolled, and at end of study for up to a maximum of 12 weeks. End and enrollment weights were used to calculate velocity.
Secondary Length Velocity Length velocity was defined as the difference in length from end of study compared to enrollment divided by the number of days enrolled in study. Length was measured at enrollment, weekly during time enrolled in study, and end of study up to a maximum of 12 weeks. End and enrollment measurements were used for velocity.
Secondary Head Circumference (OFC) Velocity OFC velocity was calculated as difference end and start of study divided by number of days enrolled in study. OFC was measured at enrollment, weekly, and end of study. Enrollment and end of study measurements used for velocity.
Secondary Average Total Calorie Intake Total calorie intake, including parenteral and enteral sources, were averaged on a weekly basis. Daily calorie intake was recorded and averaged on a weekly basis for duration of study enrollment up to max of 12 weeks.
Secondary Number of Patients With Enteral Autonomy at End of Study Percentage of patients with enteral autonomy at time of leaving or stopping study was calculated. Enteral autonomy was defined as relying on enteral nutrition only for nutrition intake with no need for parenteral nutrition supplementation. Enteral autonomy was recorded at the study end point for each individual patient. This end point was at time of stopping study lipid, discharge from hospital, or maximum of 12 weeks.
Secondary Number of Patients With Essential Fatty Acid Deficiency (EFAD) Essential fatty acid deficiency was defined as a triene to tetraene ratio greater than 0.05. Essential fatty acid levels were measured every 4 weeks during enrollment for a maximum of up to 12 weeks.
Secondary AST Change Over Time The change of AST over time was calculated and compared between groups. AST change was calculated as AST end - AST enrollment. AST was recorded at enrollment and every 2 weeks while enrolled in the study up to a maximum of 12 weeks.
Secondary ALT Change Over Time The rate of change of ALT over time was compared between groups using mixed model analysis. Change of ALT was calculated as ALT at end of study compared to ALT at enrollment. ALT measured at enrollment and every 2 weeks for max 12 weeks.
Secondary Alkaline Phosphatase Change Over Time Alkaline phosphatase was recorded at enrollment and every 2 weeks. The change in alkaline phosphatase was calculated as alkaline phosphatase at end minus enrollment. Alkaline phosphatase was measured at enrollment and every 2 weeks for max of 12 weeks.
Secondary Triglyceride Level Over Time All enrolled patients had serum triglyceride levels monitored at enrollment and weekly. The triglyceride level changes was calculated using values at the end of study compared to enrollment with mean and standard deviation calculated for each treatment group. Serum triglyceride levels monitored at enrollment and weekly during time enrolled in study for a maximum of 12 weeks.
Secondary Gamma Glutamyl Transferase (GGT) Over Time GGT was documented at baseline and regularly intervals with level compared over time between groups. GGT was compared by treatment group for levels at end of study and enrollment. GGT was measured at enrollment and every 2 weeks while enrolled in the study for a maximum of up to 12 weeks.
Secondary Number of Patients With Retinopathy of Prematurity The rate of retinopathy of prematurity (ROP) was compared between groups. ROP was diagnosed based on ophthalmologist examination with all stages included. Diagnosis was based on diagnosis during time of initial hospitalization to level 4 NICU.
Secondary Number of Patients With Bronchopulmonary Dysplasia (BPD) or Chronic Lung Disease The rate of BPD was documented and compared between groups. BPD was diagnosed based on need for respiratory support at 28 days of age. All levels of severity were included. All patient had diagnosis of BPD documented from admission at level 4 NICU.
Secondary NICU Length of Stay The length of stay at the level 4 NICU was compared between groups. Length of stay will be calculated based on documenting each patient's admission date and date leaving the NICU.
Secondary Three Year Development During the third year of chronological age an Ages and Stages questionnaire (ASQ) will be completed by the parents. ASQ will be completed anytime during the third year of life from 3 years 0 days to 3 years 364 days of chronologic age.
See also
  Status Clinical Trial Phase
Completed NCT00738101 - Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants N/A
Completed NCT03662282 - Omegaven as Alternative Parenteral Fat Nutrition Phase 3
Completed NCT02370251 - Compassionate Use of Omegaven in Children Phase 2/Phase 3
Completed NCT01072721 - Non Invasive Study of the Hepatic Fibrosis in Paediatrics by the Method of Study of Pediatric Hepatic Fibrosis N/A
Recruiting NCT05043194 - Ursodeoxycholic Acid Prevents Total Parenteral Nutrition Cholestasis N/A
Approved for marketing NCT01861834 - Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage